In this study, BCL2 and CDK2 are downregulated, and cell viability and proliferation rate are reduced after ML329 treatment in both imatinib-sensitive and -resistant GIST cell lines. This evidence concerns the gene CDK2 and gastrointestinal stromal tumor.